CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 41 enrolled
Drug / intervention
florbetapir F 18 +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02079766
NCT02079766Phase 2Completed
CompareCT.gov

18F-AV-1451 and Florbetapir F 18 PET Imaging in Subjects With Repetitive Brain Trauma at High Risk for Chronic Traumatic Encephalopathy

Avid Radiopharmaceuticals·interventional·Posted Mar 6, 2014·Updated Sep 7, 2020

In Brief

A Phase 2 clinical trial evaluating florbetapir F 18 and Flortaucipir F18 for Chronic Traumatic Encephalopathy. Completed, enrolled 41 participants across 2 sites.

Detailed Summary

This study will explore the use of flortaucipir as a biomarker for chronic traumatic encephalopathy (CTE) and examine the relationship between clinical presentation and tau deposition.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsChronic Traumatic Encephalopathy
CountriesUnited States
Collaborators--

Timeline

Phase 2CompletedFinished
2014201520162017201820192020202120222023202420252026
First PostedMar 6, 2014
Enrollment StartJun 1, 2014
Primary CompletionOct 1, 2015
TodayJul 2, 2026
Enrollment to primary: 1.3 yearsPosted 12.3 years ago

Interventions

florbetapir F 18drug

370 megabecquerel (MBq) IV single-dose

Flortaucipir F18drug

370 megabecquerel (MBq) IV single-dose